Mersana Therapeutics (NASDAQ:MRSN) is a biotechnology firm focused on developing transformative antibody-drug conjugates (ADCs) for treating various forms of cancer. Specializing in leveraging its proprietary platform to create drug conjugates that aim to improve outcomes for cancer patients, Mersana's operations span from drug discovery through clinical trials. The company's projects include a pipeline of novel ADCs targeting both solid tumors and hematological malignancies, with multiple drugs currently undergoing clinical evaluation. Mersana's objectives revolve around advancing its research and development efforts to bring innovative cancer therapies to market, ultimately improving patient care and expanding treatment options for oncologists and their patients. Through rigorous scientific research and clinical development, Mersana seeks to make a significant impact in oncology.